(TEM) Tempus AI, Common Stock - Overview
Stock: Diagnostics, Analytics, Insights, Trials, Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.3% |
| Relative Tail Risk | -7.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -53.02 |
| Character TTM | |
|---|---|
| Beta | 2.451 |
| Beta Downside | 1.828 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.99% |
| CAGR/Max DD | 0.35 |
Description: TEM Tempus AI, Common Stock December 19, 2025
Tempus AI, Inc. (NASDAQ: TEM) is a Chicago-based healthcare technology firm that delivers next-generation sequencing, PCR profiling, molecular genotyping, and other anatomic and molecular pathology services to a broad client base that includes health systems, pharma, biotech, and research institutions.
Its product ecosystem consists of Insights (a de-identified library linking clinical, molecular and imaging data), Trials (clinical-trial matching for pharma), Next (algorithmic oncology tests), Hub (a desktop/mobile ordering and results platform), and Lens (a researcher-focused data discovery tool.
The company has forged strategic collaborations with AstraZeneca and Pathos AI to co-develop oncology therapeutics, and maintains partnerships with Personalis Inc. and Whitehawk Therapeutics to expand its data-driven drug-development capabilities. Tempus rebranded from Tempus Labs to Tempus AI in January 2023 and has been publicly traded since 2021.
Key market metrics: FY 2023 revenue reached roughly $1.1 billion, up ≈30 % YoY, reflecting strong demand for precision-medicine diagnostics; the global precision oncology market is projected to exceed $30 billion by 2028, providing a sizable addressable base. Tempus’s cash runway extends through 2026, but its operating loss remains elevated (~$200 million), underscoring the need for continued scale-up and monetization of its data platforms.
For a deeper, data-driven valuation perspective, you may find ValueRay’s analytical framework useful for digging into TEM’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -203.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 10.42 > 1.0 |
| NWC/Revenue: 72.06% < 20% (prev 66.64%; Δ 5.42% < -1%) |
| CFO/TA -0.10 > 3% & CFO -220.6m > Net Income -203.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (174.9m) vs 12m ago 5.64% < -2% |
| Gross Margin: 61.36% > 18% (prev 0.53%; Δ 6083 % > 0.5%) |
| Asset Turnover: 67.95% > 50% (prev 65.91%; Δ 2.04% > 0%) |
| Interest Coverage Ratio: -2.55 > 6 (EBITDA TTM -89.7m / Interest Expense TTM 68.3m) |
Altman Z'' -3.16
| A: 0.35 (Total Current Assets 1.15b - Total Current Liabilities 350.0m) / Total Assets 2.28b |
| B: -1.03 (Retained Earnings -2.34b / Total Assets 2.28b) |
| C: -0.11 (EBIT TTM -174.6m / Avg Total Assets 1.63b) |
| D: -1.32 (Book Value of Equity -2.34b / Total Liabilities 1.77b) |
| Altman-Z'' Score: -3.16 = D |
Beneish M -1.96
| DSRI: 1.15 (Receivables 288.6m/145.6m, Revenue 1.11b/640.4m) |
| GMI: 0.87 (GM 61.36% / 53.18%) |
| AQI: 1.90 (AQ_t 0.43 / AQ_t-1 0.23) |
| SGI: 1.73 (Revenue 1.11b / 640.4m) |
| TATA: 0.01 (NI -203.9m - CFO -220.6m) / TA 2.28b) |
| Beneish M-Score: -1.96 (Cap -4..+1) = B |
What is the price of TEM shares?
Over the past week, the price has changed by -8.21%, over one month by -21.04%, over three months by -23.83% and over the past year by -15.51%.
Is TEM a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 87.9 | 60.1% |
| Analysts Target Price | 87.9 | 60.1% |
| ValueRay Target Price | 51.3 | -6.7% |
TEM Fundamental Data Overview February 03, 2026
P/B = 22.2496
Revenue TTM = 1.11b USD
EBIT TTM = -174.6m USD
EBITDA TTM = -89.7m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 12.4m USD (from shortTermDebt, last quarter)
Debt = 1.34b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 679.9m USD (from netDebt column, last quarter)
Enterprise Value = 11.22b USD (10.64b + Debt 1.34b - CCE 759.6m)
Interest Coverage Ratio = -2.55 (Ebit TTM -174.6m / Interest Expense TTM 68.3m)
EV/FCF = -45.22x (Enterprise Value 11.22b / FCF TTM -248.1m)
FCF Yield = -2.21% (FCF TTM -248.1m / Enterprise Value 11.22b)
FCF Margin = -22.45% (FCF TTM -248.1m / Revenue TTM 1.11b)
Net Margin = -18.45% (Net Income TTM -203.9m / Revenue TTM 1.11b)
Gross Margin = 61.36% ((Revenue TTM 1.11b - Cost of Revenue TTM 427.0m) / Revenue TTM)
Gross Margin QoQ = 61.61% (prev 61.99%)
Tobins Q-Ratio = 4.92 (Enterprise Value 11.22b / Total Assets 2.28b)
Interest Expense / Debt = 1.15% (Interest Expense 15.4m / Debt 1.34b)
Taxrate = 21.0% (US default 21%)
NOPAT = -137.9m (EBIT -174.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.28 (Total Current Assets 1.15b / Total Current Liabilities 350.0m)
Debt / Equity = 2.63 (Debt 1.34b / totalStockholderEquity, last quarter 507.8m)
Debt / EBITDA = -7.58 (negative EBITDA) (Net Debt 679.9m / EBITDA -89.7m)
Debt / FCF = -2.74 (negative FCF - burning cash) (Net Debt 679.9m / FCF TTM -248.1m)
Total Stockholder Equity = 300.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.53% (Net Income -203.9m / Total Assets 2.28b)
RoE = -67.96% (Net Income TTM -203.9m / Total Stockholder Equity 300.0m)
RoCE = -11.30% (EBIT -174.6m / Capital Employed (Equity 300.0m + L.T.Debt 1.25b))
RoIC = -12.32% (negative operating profit) (NOPAT -137.9m / Invested Capital 1.12b)
WACC = 13.38% (E(10.64b)/V(11.98b) * Re(14.95%) + D(1.34b)/V(11.98b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 14.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.52%
Fair Price DCF = unknown (Cash Flow -248.1m)
EPS Correlation: 86.18 | EPS CAGR: 754.4% | SUE: 0.53 | # QB: 0
Revenue Correlation: 96.86 | Revenue CAGR: 54.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.47 | Chg30d=+0.002 | Revisions Net=-1 | Growth EPS=+23.7% | Growth Revenue=+24.3%